Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

Exclusion Criteria

• •Type 1 Diabetes Mellitus (T1DM)
• •T2DM with history of or current insulin therapy. Prior use during pregnancy or gestational diabetes was acceptable.
• •History of ketoacidosis or ketosis-prone diabetes
• •Clinically significant complications of diabetes that in the judgment of the investigator would have made participant unsuitable to participate in this trial
• •History of a severe episode of hypoglycemia
• •Change in non-insulin antidiabetic therapy in addition to diet and exercise \< 2 months prior to screening
• •Any clinically significant cardiovascular event \< 2 months prior to screening
• •Clinically significant, inadequately controlled or unstable hypertension
• •Hospitalization \< 2 months prior to screening
• •Major surgery \< 3 months prior to screening
• •Weight loss medication (prescription or non-prescription) \< 2 months prior to screening